These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 19628315)

  • 1. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
    Servilla KS; Singh AK; Hunt WC; Harford AM; Miskulin D; Meyer KB; Bedrick EJ; Rohrscheib MR; Tzamaloukas AH; Johnson HK; Zager PG
    Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perihospitalization hemoglobin-epoetin associations in U.S. hemodialysis patients, 1998 to 2003.
    Solid CA; Foley RN; Gilbertson DT; Collins AJ
    Hemodial Int; 2007 Oct; 11(4):442-7. PubMed ID: 17922742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.
    Xue JL; St Peter WL; Ebben JP; Everson SE; Collins AJ
    Am J Kidney Dis; 2002 Dec; 40(6):1153-61. PubMed ID: 12460033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
    Go AS; Yang J; Ackerson LM; Lepper K; Robbins S; Massie BM; Shlipak MG
    Circulation; 2006 Jun; 113(23):2713-23. PubMed ID: 16754803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
    Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
    J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring relative mortality and epoetin alfa dose among hemodialysis patients.
    Bradbury BD; Wang O; Critchlow CW; Rothman KJ; Heagerty P; Keen M; Acquavella JF
    Am J Kidney Dis; 2008 Jan; 51(1):62-70. PubMed ID: 18155534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access.
    Lacson E; Wang W; Hakim RM; Teng M; Lazarus JM
    Am J Kidney Dis; 2009 Jan; 53(1):79-90. PubMed ID: 18930570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of anemia and hyperhomocysteinemia on mortality of patients on hemodialysis.
    Anees M; Mumtaz A; Ibrahim M; Shaheen SM; Asghar A
    Iran J Kidney Dis; 2010 Jan; 4(1):60-5. PubMed ID: 20081306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
    Bradbury BD; Do TP; Winkelmayer WC; Critchlow CW; Brookhart MA
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):932-40. PubMed ID: 19572312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
    Weinhandl ED; Gilbertson DT; Collins AJ
    Am J Nephrol; 2011; 34(4):298-308. PubMed ID: 21829009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlates affecting survival in chronic hemodialysis patients: the combined impact of albumin and high hemoglobin levels on improving outcomes, local and national results.
    Capelli JP; Kushner H
    Hemodial Int; 2008 Oct; 12(4):450-62. PubMed ID: 19090868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
    Berns JS
    Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients.
    Chan K; Moran J; Hlatky M; Lafayette R
    Nephrol Dial Transplant; 2009 Jun; 24(6):1956-62. PubMed ID: 19176685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis.
    Amaral S; Hwang W; Fivush B; Neu A; Frankenfield D; Furth S
    J Am Soc Nephrol; 2006 Oct; 17(10):2878-85. PubMed ID: 16943308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis.
    St Peter WL; Li S; Liu J; Gilbertson DT; Arneson TJ; Collins AJ
    Pharmacotherapy; 2009 Feb; 29(2):154-64. PubMed ID: 19170585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hemoglobin variability in patients with chronic renal insuffiency].
    Deray G
    Nephrol Ther; 2008 Dec; 4(7):549-52. PubMed ID: 19004677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia.
    Piccoli A; Malagoli A; Komninos G; Pastori G
    J Nephrol; 2002; 15(5):565-74. PubMed ID: 12455725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.